Aimmune Therapeutics (NASDAQ: AIMT) announced that it has received the European Medicines Agency (EMA) decision endorsing the company’s pediatric investigation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE